List of Excipients in Branded Drug UZEDY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Pharmaceuticals USA Inc	UZEDY	risperidone	51759-305	DIMETHYL SULFOXIDE

UZEDY Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: August 4, 2026

UZEDY is Teva Pharmaceuticals’ extended-release risperidone injection for schizophrenia. Its formulation uses a biodegradable polymer depot with N-methyl-2-pyrrolidone (NMP), enabling subcutaneous administration once monthly or once every two months. The main commercial opportunity is not a new active ingredient. It is the combination of dosing flexibility, subcutaneous delivery, reduced administration burden, and protection around the depot formulation and manufacturing process.

The formulation also creates commercial constraints. NMP and poly(DL-lactide-co-glycolide), or PLGA, require tight control of local tolerability, polymer attributes, residual solvent, particle characteristics, release kinetics, and syringe compatibility. Those controls create barriers for generic developers and potential licensing opportunities for excipient, delivery-system, and manufacturing partners.

What excipients are used in UZEDY?

UZEDY contains risperidone, PLGA, and NMP. The FDA prescribing information identifies the inactive ingredients as poly(DL-lactide-co-glycolide) and N-methyl-2-pyrrolidone.[1]

Formulation component	Function in UZEDY	Commercial and regulatory significance
Risperidone	Active antipsychotic	Established molecule with generic oral competition
PLGA	Biodegradable depot-forming polymer	Controls drug release and creates formulation-specific technical barriers
NMP	Solvent and vehicle	Helps form the injectable depot after subcutaneous administration; requires controls for tolerability and residual solvent
Prefilled syringe system	Primary container and delivery device	Requires compatibility, extractables, leachables, viscosity, and injection-force validation

UZEDY is supplied as an extended-release injectable suspension in a prefilled syringe. The product is administered subcutaneously by a healthcare professional, unlike several competing long-acting antipsychotics that use intramuscular injection.[1]

How does the PLGA depot work?

PLGA is a biodegradable copolymer commonly used in controlled-release drug delivery. After injection, the polymer matrix gradually hydrolyzes and erodes. Risperidone is released over time through a combination of diffusion and polymer degradation.

The commercial value of PLGA is determined by more than the polymer’s chemical identity. Relevant attributes include:

• Lactide-to-glycolide ratio
• Polymer molecular weight
• End-group chemistry
• Residual monomer and solvent levels
• Particle-size distribution
• Drug loading
• Porosity and morphology
• Water content
• In-vitro release profile
• Sterility and endotoxin control

A generic manufacturer may be able to purchase pharmaceutical-grade PLGA, but matching UZEDY’s release profile and injection behavior remains a complex formulation and process-development exercise.

What is the role of NMP?

NMP is a water-miscible organic solvent used in injectable depot systems. In a PLGA-based formulation, it helps maintain the drug-polymer system in an injectable state and contributes to depot formation after administration.

NMP creates several development obligations:

1. Demonstrating acceptable local tissue tolerability.
2. Controlling residual solvent and impurity levels.
3. Establishing syringe and elastomer compatibility.
4. Managing viscosity and injection force.
5. Controlling the rate at which solvent exchanges with surrounding tissue fluid.
6. Demonstrating consistent depot formation across dose strengths.

The solvent-polymer interaction is likely to be as important as the nominal excipient list. A formulation that uses the same PLGA and NMP may still fail to reproduce the same clinical release characteristics if the manufacturing process, polymer grade, solids content, or particle structure differs.

What is the FDA regulatory status of UZEDY?

The FDA approved UZEDY in April 2023 under New Drug Application 215211 for the treatment of schizophrenia in adults.[2] The product is available in monthly and every-two-month dosing regimens.

UZEDY is intended for patients who have established tolerability to oral risperidone. The approved strengths support dose conversion from oral risperidone without requiring a loading dose or oral supplementation after the first injection, according to the prescribing information.[1]

Regulatory milestone	Date or status
FDA approval	April 2023
NDA	215211
Active ingredient	Risperidone
Dosage form	Extended-release injectable suspension
Route	Subcutaneous
Dosing intervals	Once monthly or once every two months
Therapeutic area	Schizophrenia
Administration	Healthcare professional

The FDA approval gives Teva a regulatory platform for additional studies involving adherence, earlier intervention, maintenance treatment, and possible use in related risperidone-treated populations. Any expansion would require new clinical and regulatory support.

What patents protect UZEDY and its excipient strategy?

UZEDY’s protection is likely to involve a combination of formulation, dosage, administration, manufacturing, and drug-device claims rather than protection for risperidone itself. Risperidone has long been generic in oral dosage forms, so the principal intellectual-property value lies in the long-acting delivery system.

Potential claim categories include:

• PLGA-based risperidone depot compositions
• Specific polymer-to-drug ratios
• NMP-containing injectable suspensions
• Particle-size and release-rate limitations
• Monthly and two-month dosing regimens
• Subcutaneous administration
• Conversion from oral risperidone
• Prefilled syringe configurations
• Manufacturing and sterilization processes
• Stability and suspension-control methods

FDA Orange Book entries, if listed, are relevant to U.S. generic timing and Paragraph IV exposure. The FDA Orange Book should be reviewed for current patent numbers, expiration dates, pediatric exclusivity, and any patent-use codes associated with NDA 215211.[3]

The most durable protection may sit outside a narrow excipient claim. A formulation patent that claims only PLGA and NMP can face design-around pressure if competitors use different polymer grades, solvents, particle structures, or depot-forming mechanisms. Claims tied to measurable pharmacokinetic behavior, injection performance, or a defined release profile can be more difficult to design around, but may create validity and infringement disputes over claim construction and testing methods.

When does UZEDY lose exclusivity?

UZEDY’s exclusivity timeline has two separate components: regulatory exclusivity and patent protection.

Regulatory exclusivity

UZEDY received approval in 2023. New chemical entity exclusivity is not expected to apply because risperidone was previously approved. The product’s protection is therefore more dependent on patents, formulation differentiation, and the practical difficulty of developing a substitutable long-acting injectable.

The approval may also benefit from three-year clinical-investigation exclusivity for new clinical investigations supporting the new dosage form or delivery system, subject to FDA determination of eligibility. That protection would generally be narrower than NCE exclusivity and would not necessarily block all abbreviated applications.

Patent expiration

Patent expiration dates depend on the patents listed for NDA 215211 and on any applicable patent-term adjustment or extension. A responsible market-entry forecast should distinguish:

• Earliest formulation-patent expiration
• Earliest enforceable patent expiration
• Method-of-use patent expiration
• Pediatric exclusivity, if granted
• Litigation-related launch restrictions
• Potential at-risk launch dates
• Approval timing for a competing complex injectable

Because UZEDY is a complex injectable suspension, a nominal patent expiry may not produce immediate commercial substitution. FDA review of a generic or follow-on injectable can require substantial comparative chemistry, manufacturing, and controls information.

What generic entry risks exist for UZEDY?

Generic entry risk is moderate to high over the long term but lower than for an ordinary oral risperidone product.

Why generic development is difficult

A competing product must address:

• Extended-release equivalence
• In-vitro release matching
• Particle morphology
• Polymer degradation
• NMP content and solvent exchange
• Injection-site tolerability
• Syringe compatibility
• Sterility assurance
• Dose proportionality across strengths
• Clinical pharmacokinetic comparability

The regulatory pathway may not be as simple as copying an immediate-release tablet. FDA requirements for complex injectable products can create substantial development time and manufacturing cost.

Paragraph IV challenges

A Paragraph IV applicant could challenge listed patents by alleging that the patents are invalid, unenforceable, or not infringed. Likely challenge targets would include:

• Broad PLGA/NMP composition claims
• Dose and dosing-interval claims
• Subcutaneous administration claims
• Release-profile claims
• Manufacturing claims with limited practical scope

Teva could respond with patent litigation under the Hatch-Waxman framework. A filing would generally trigger a 30-month stay of FDA approval, subject to statutory exceptions and litigation outcomes.[4]

The highest litigation risk would arise if a generic applicant can show that its formulation uses a different polymer architecture or solvent system while achieving comparable pharmacokinetics. The strongest defense would involve claims that capture the product’s functional release characteristics, not only its named ingredients.

How does UZEDY compare with competing long-acting antipsychotics?

UZEDY competes in a crowded long-acting injectable market dominated by branded products with different dosing intervals and delivery routes.

Product	Active ingredient	Route	Typical dosing interval	Key differentiation
UZEDY	Risperidone	Subcutaneous	Monthly or every two months	Flexible dosing and SC depot delivery
Perseris	Risperidone	Subcutaneous	Monthly	Earlier SC risperidone depot product
Risperdal Consta	Risperidone	Intramuscular	Every two weeks	Established product but more frequent administration
Invega Sustenna	Paliperidone palmitate	Intramuscular	Monthly	Broad use and established clinical adoption
Invega Trinza	Paliperidone palmitate	Intramuscular	Every three months	Longer dosing interval
Invega Hafyera	Paliperidone palmitate	Intramuscular	Every six months	Longest marketed interval among major products
Abilify Maintena	Aripiprazole	Intramuscular	Monthly	Partial dopamine agonist
Aristada	Aripiprazole lauroxil	Intramuscular	Monthly to every six months, depending on regimen	Extended interval and aripiprazole mechanism

UZEDY’s main advantages are subcutaneous administration and a monthly or two-month interval. Its main competitive disadvantage is that six-month paliperidone products offer a longer interval for patients who qualify and tolerate them.

Perseris is the closest formulation competitor because it also uses subcutaneous risperidone delivery. UZEDY’s two-month option gives it a potential adherence and convenience advantage over monthly Perseris, while Perseris benefits from earlier market presence.

What commercial opportunities exist for UZEDY excipients?

The commercial opportunities extend beyond direct sales of PLGA and NMP.

Excipient supply

Qualified suppliers can compete for:

• Pharmaceutical-grade PLGA
• Controlled molecular-weight polymer batches
• Low-endotoxin polymer
• Low-moisture polymer
• NMP meeting injectable-grade specifications
• Container-closure components
• Low-sorption syringe materials

Supply agreements may be valuable because polymer lot variability can affect drug release and product consistency. A supplier that can provide narrow attribute ranges, long-term capacity, and regulatory documentation has a stronger position than a commodity chemical supplier.

Formulation licensing

Drug-delivery companies may license:

• Alternative biodegradable polymers
• Solvent-free depot systems
• In-situ forming implants
• Microparticle suspensions
• Longer-interval risperidone systems
• Lower-viscosity formulations
• High-concentration formulations
• Autoinjector-compatible delivery systems

A successful alternative would need to preserve the clinical advantages of UZEDY while reducing NMP exposure, injection discomfort, manufacturing complexity, or supply-chain dependence.

Manufacturing partnerships

Contract development and manufacturing organizations can target:

• Polymer-drug mixing
• Aseptic suspension processing
• Prefilled syringe filling
• In-process particle characterization
• Release testing
• Stability programs
• Scale-up and technology transfer

The highest-value opportunity is likely integrated development and manufacturing rather than supply of a single excipient.

What formulation improvements could create new product opportunities?

Potential lifecycle strategies include:

1. A lower-volume injection with equivalent exposure.
2. A six-month formulation to compete with long-interval paliperidone.
3. A formulation with reduced NMP content.
4. A prefilled autoinjector for controlled administration.
5. A formulation with reduced injection-site pain.
6. A pediatric or adolescent development program, if clinically justified.
7. A combination adherence program linked to digital administration records.
8. A formulation suitable for outpatient or community-clinic use.
9. A product with simplified storage requirements.
10. A higher-concentration formulation that reduces administration time.

Each strategy would face different regulatory and patent hurdles. A new dosing interval could support method-of-use or formulation claims, while a new device could support device and combination-product claims.

What is the revenue exposure and market outlook for UZEDY?

UZEDY’s revenue opportunity depends on conversion from oral risperidone, Perseris, Risperdal Consta, and paliperidone products. The addressable market includes adults with schizophrenia who have adherence problems, relapse risk, unstable treatment access, or preference for less frequent administration.

Commercial adoption will depend on:

• Reimbursement and prior authorization
• Buy-and-bill economics
• Provider training
• Injection-site acceptability
• Availability of monthly and two-month doses
• Patient access to outpatient psychiatric care
• Competition from six-month products
• Teva’s sales-force coverage
• Real-world adherence outcomes

The product’s revenue profile should be modeled as a conversion opportunity within the long-acting injectable market, not as a replacement for all oral risperidone use. The strongest accounts are likely community mental-health clinics, Medicaid-heavy systems, integrated behavioral-health networks, and providers managing recurrent nonadherence.

Key Takeaways

• UZEDY uses risperidone with PLGA and NMP in a subcutaneous extended-release depot.
• The excipient strategy creates value through controlled release, flexible dosing, and subcutaneous administration.
• PLGA quality attributes and NMP-polymer behavior are central to product performance.
• The principal IP value is likely in formulation, dosing, administration, manufacturing, and device claims.
• Generic entry is more difficult than for oral risperidone because UZEDY is a complex injectable suspension.
• Perseris is the closest formulation competitor; paliperidone and aripiprazole products create broader market pressure.
• Commercial opportunities include qualified excipient supply, depot-platform licensing, contract manufacturing, device integration, and longer-interval formulations.
• The most important lifecycle opportunity is a formulation that extends dosing beyond two months while maintaining tolerability and predictable exposure.

FAQs

Can PLGA alone be used to make a generic version of UZEDY?

No. PLGA is a widely used excipient, but a substitutable product would need to match critical formulation and performance attributes, including release kinetics, particle structure, injection behavior, stability, and pharmacokinetics.

Is NMP an active ingredient in UZEDY?

No. NMP is an inactive solvent and vehicle used in the depot formulation. Its concentration, residual level, tissue tolerability, and interaction with PLGA are important CMC parameters.

Does UZEDY have biosimilar competition?

No. UZEDY is a small-molecule risperidone product, not a biologic. Potential competitors would generally be generic, follow-on, or other complex injectable products rather than biosimilars.

Can UZEDY be administered at home?

The FDA labeling identifies administration by a healthcare professional. A future home-use opportunity would likely require a suitable delivery device, training model, and regulatory support.

Which excipient presents the greatest development barrier?

PLGA is likely the greater technical barrier because polymer attributes directly affect depot structure and release. NMP creates important safety, compatibility, and manufacturing controls, but the combined polymer-solvent system is the core formulation challenge.

References

1. U.S. Food and Drug Administration. (2023). UZEDY (risperidone) extended-release injectable suspension: Prescribing information. Teva Pharmaceuticals USA, Inc.

2. U.S. Food and Drug Administration. (2023). FDA approves extended-release injectable suspension for schizophrenia. Drugs@FDA, NDA 215211.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/fdas-drug-evaluation-process-drug-development/abbreviated-new-drug-application-anda